(July 20, 2015 – Denver, CO) Criterium, Inc., a full-service CRO is pleased to announce the promotions of our two newest consortia directors, Drs. D. Ross Camidge and Peter Kabos, both from the University of Colorado. Dr. Camidge, Director for the ATOMIC Consortia for Thoracic and Lung Cancers, was recently promoted from his current position of Associate Professor, Division of Medical Oncology to “Professor with Tenure”. Dr. Kabos, Director for the ABRCC Consortia for Breast Cancer, was recently promoted from his current position of Assistant Professor, Division of Medical Oncology to “Associate Professor”.
Dr. Camidge was educated at Cambridge University (MRC Laboratory of Molecular Biology, Cambridge, UK – 1992); and Oxford University Medical School, (Oxford, UK – 1995). He joined the University of Colorado as a visiting professor in November of 2005, and was recruited as full-time faculty at UCD in October of 2007. He helped to found and establish the ATOMIC Consortia as a premiere research group in 2013.
Dr. Kabos completed his Internal Medicine residency training at USC Keck School of Medicine in Los Angeles and a fellowship in Hematology/Oncology at the University of Colorado Denver. He joined the UCD faculty in July 2009 and was a member of the breast oncology program. He is the driving force of The Kabos Research Lab for Breast Cancer, which bears his name. He helped to found and establish the ABRCC Consortia as a front running research group in 2014.
Criterium, Inc. is a full-service, global CRO (contract research organization) that offers a unique mix of high-quality clinical research services and communication processes for the biopharmaceutical, pharmaceutical, and medical device industries to manage trials from initial planning to approval. Founded in 1991, Criterium’s services are customized to fit each client’s specific needs, providing a seamless flow of data and information from the investigative site through Criterium and back to the sponsor – 24/7, in real-time. Criterium’s experienced team manages and implements clinical trials using technology-based solutions. Dedicated clinical professionals are committed to providing personal service and to forming strong and productive relationships with clients. Criterium’s well-established staff are trained according to ICH GCP guidelines.
The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise: The Academic GI Cancer Consortium (AGICC) is presently represented by Key Opinion Leaders (KOLs) and top Investigators at 16 of the most prestigious institutions in the USA. The Academic Myeloma Cancer Consortium (AMyC) is represented by Key Opinion Leaders (KOLs) and top Investigators at 9 of the most prestigious institutions in the USA. The Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) is represented by Key Opinion Leaders (KOLs) and top Investigators at 12 of the most prestigious institutions in the USA. The Academic Breast Cancer Consortium (ABRCC) is represented by Key Opinion Leaders (KOLs) and top Investigators at 14 of the most prestigious institutions in the USA.
Corporate headquarters are located in Saratoga Springs, New York with satellite offices in Florida & California, and in-country representation in South Africa, India, Canada, The EU, Israel, and Russia. This multi-national approach enables Criterium to provide time- and cost-efficient study management and monitoring to all our clients. To learn more about Criterium, visit the website www.criteriuminc.com.
Available for Immediate Release
Contact: Claire R. Wynters, Public Relations & Media – (518) 583-0095 or email@example.com